A 50-year-old male presented for a Whipple's procedure to excise a pancreatic lesion. Massive transfusion of packed cells and fresh frozen plasma was required. Towards the end of the procedure, the patient developed sudden onset of frank pulmonary oedema and hypotension. A presumptive diagnosis of transfusion related lung injury was made after prompt investigations excluded circulatory overload or cardiogenic shock as the cause. This case report describes an increasingly common and life-threatening sequela of blood product transfusion, the management of which is complicated by the current lack of specific diagnostic tests.
Transfusion-related lung injury (TRALI) is a type of acute respiratory distress syndrome (ARDS), which occurs following transfusion of plasma containing blood products 1 . It is a serious, frequently fatal immune-mediated condition, typically caused by the reaction of antibodies in the donor unit to leucocyte antigens in the recipient. The condition presents with the sudden onset of non-cardiogenic pulmonary oedema during, or several hours after, transfusion of a blood component. There is no specific test for TRALI; diagnosis is a clinical one. Therefore despite being the commonest cause of mortality and serious morbidity resulting from transfusion, the condition remains underdiagnosed and underreported 2 .
CASE HISTORY
A 50-year-old Caucasian male presented for a Whipple's procedure to treat a cyst in the head of his pancreas. The patient had type II diabetes for which he was receiving gliclazide. There was no history of cardiorespiratory disease, and his ECG was normal. Preoperative blood tests, including liver function tests, amylase, and coagulation screen were normal. Renal function was also normal.
With full anaesthetic monitoring and intravenous access, anaesthesia was induced with propofol 200 mg and fentanyl 350 µg. Rocuronium 50 mg IV was ad-ministered to facilitate endotracheal intubation with a 7.5 mm endotracheal tube. Arterial and central venous catheters were inserted in the left radial artery and the right internal jugular vein respectively. A nasal temperature probe and urinary catheter were sited. Anaesthesia was maintained with sevoflurane in oxygen. Further fentanyl was given as required.
The patient remained stable until three hours into the operation when surgical bleeding from the portal vein occurred. The patient received eight units of packed red blood cells and four units of fresh frozen plasma (FFP) over 60 min. The measured blood loss was 4500 ml. The patient stabilized when the surgeons obtained haemostasis. At the time, the heart rate (HR) was 80/min, blood pressure (BP) 90/ 40 mmHg and central venous pressure 15 mmHg. The urine output had been 50 ml per hour for the previous two hours. Core temperature was 36.1°C. Full blood count and coagulation studies showed haemoglobin 86 g/l (preoperative value 124 g/l), platelets 98x10 9 /l, APTT 41 s and INR 1.6. A further four units of FFP were administered over the next four hours.
During administration of the final unit of FFP the airway pressures suddenly increased. This was followed by the appearance of copious yellow, frothy secretions in the endotracheal tube. Chest auscultation revealed bilateral crepitations. Simultaneously, BP dropped to 70/35 mmHg, HR increased to 110/min and central venous pressure decreased from 15 mmHg to 8 mmHg. Pulmonary oedema was diagnosed and frusemide 80 mg was administered with no effect. Following five intravenous adrenaline boluses of 100 µg, an adrenaline infusion was commenced to maintain BP above 100 mmHg systolic. Intravenous hydrocortisone 200 mg was administered. Manual ventilation was required as the peak airway pressure (PAP) had increased to 70 cmH 2 O. An arterial blood sample showed a mixed respiratory and metabolic acidosis with pH=7.05, PCO 2 =108 mmHg, PO 2 = 128 mmHg, base excess (BE)=-5.0 mmol/l -1 , and haemoglobin=163 g/l. An urgent transoesophageal echocardiogram was performed which showed a well filled right ventricle, normal right and left ventricular function, and no valvular lesions. Non-cardiogenic pulmonary oedema was diagnosed. A reaction to FFP was suspected and the transfusion was stopped.
The patient was transferred to the intensive care unit (ICU) where he continued to deteriorate despite supportive therapy. The differential diagnosis included acute respiratory distress syndrome (ARDS) or shock secondary to pancreatitis, sepsis, massive transfusion, anaphylaxis, or a transfusion reaction. Inotropic support was increased with the addition of dobutamine and noradrenaline infusions. Blood pressure was 85/45 mmHg, the heart rate was 150/min, and the patient was peripherally vasoconstricted. Arterial blood gases showed worsening hypoxia and acidosis (PO 2 =84 mmHg, pH=7.12, PCO 2 = 61 mmHg, BE=-11.7 with an FiO 2 =1.0 and PEEP= 13 cmH 2 O). Lung compliance remained low with PAP =38 cmH 2 O on pressure controlled ventilation. Nitric oxide therapy was commenced. Urine output decreased to 20 ml per hour and creatinine increased to 160 µmol/l. Neutrophilia of 10.79×10 9 /l occurred within a few hours of the reaction followed by neutropenia of 1.06×10 9 /l over the subsequent days. Serum albumin fell from 45 g/l to 24 g/l within two hours of the reaction. Over the next 48 hours oxygenation improved and inotropic requirements decreased. Inotropes were withdrawn on the third postoperative day and the patient was extubated. The patient was discharged from ICU the following day and went home six days later.
LABORATORY INVESTIGATION
The case was referred to the blood transfusion department as a suspected transfusion reaction. Tests confirmed that the patient received blood group and cross-matched compatible blood products. The patient's IgA level was normal on both pre and post transfusion samples and antibodies to IgA were not detected in either sample. Testing for antibodies to human leucocyte antigens (HLA) and human neutrophil antigens (HNA) in the patient were negative. The Australian Red Cross Blood Service (ARCBS North West Region) were informed of the reaction and the donors involved. ARCBS arranged testing of donors at the time of their next donation for anti-HLA and anti-HNA antibodies ( Table 1) . Bacterial testing of blood products was not possible as only one empty FFP container was returned to the transfusion unit. The patient received 15 separate blood product units (8 packed cells and 7 FFP). The FFP transfused at the time of the reaction (number 15) was the only product of those tested in which weak reactions to anti-HLA class 1 were detected. However, strong anti-HLA class II antibodies were also detected in the same FFP product. Two of the red cell donors have not returned to the ARCBS for a further blood donation and remain untested. The patient was discharged from hospital without HLA typing being performed. The presence of antibodies to HLA class I and II in the FFP being transfused at the time of the reaction adds to the clinical picture and suspicion that this was a transfusion reaction and TRALI was the most likely cause of the patient's respiratory condition.
DISCUSSION
Transfusion-related acute lung injury was first reported in the 1950s and is a well described clinical entity. Lately, it has received a great deal of attention in the medical literature 1, 4, 7 . The Serious Hazards of Transfusion (SHOT) 2001 report 8 , showed that TRALI is the second most common cause of transfusion-related mortality and morbidity in the U.K., after ABO incompatibility. The latest report, SHOT 2003 13, shows that the number of reported cases has increased again, although it is not possible to say whether this reflects a true increased incidence or just an increased awareness of the condition.
TRALI is a particular form of acute respiratory distress syndrome (ARDS) due to transfusion of blood products, specifically plasma. Every commonly used blood component that contains plasma has been implicated in causing TRALI; the predominant components are platelets, fresh frozen plasma, whole blood, packed red blood cells, cryoprecipitate, and white blood cells 10 . TRALI has a reported incidence of 1 per 5000 units transfused 9 . There are about 15 reports per year in the U.K. with an associated mortality of 25% 8 and it is likely to be under reported 1 . There are an estimated 500 TRALI-related deaths per year in the USA alone 2 . On average, four new cases per year were reported in Australia between 1999 and 2001 4 .
The initial clinical presentation of TRALI is indistinguishable from ARDS 9 . It can occur up to 24 hours after transfusion, but the onset is usually within the first six hours 1, 8, 13 . There is sudden onset of noncardiogenic pulmonary oedema with production of copious frothy fluid and rapid onset of severe hypoxia. Physical examination reveals signs of pulmonary oedema with bilateral crepitations and decreased breath sounds 1, 11 . The chest X-ray demonstrates bilateral diffuse fluffy infiltrates typical of ARDS. Seventy per cent of affected patients require mechanical ventilation 9 . Associated non-respiratory findings are hypotension, hypovolaemia, fever, haemoconcentration, hypoalbuminaemia and neutrophilia 1 .
Frequently, suspected cases are complex and it may be impossible to distinguish TRALI from other causes, which include transfusion associated circulatory overload (TACO), cardiogenic shock, other causes of ARDS, sepsis, transfusion mismatch or anaphylaxis 10 . The diagnosis of TRALI must be a clinical one as it is essentially a diagnosis of exclusion of other causes. Moreover, rapid confirmatory immunological test results are not available to confirm the diagnosis.
The precise mechanism of pathogenesis has not been defined but a growing body of evidence points to an immunologically mediated event, often triggered by donor units containing anti-leucocyte antibodies. Anti-HLA class I and II and anti-HNA antibodies are the most common cause of a TRALI reaction. These antibodies activate recipient leucocytes, which cause microvascular occlusion, endothelial damage and capillary leakage, resulting in pulmonary injury. Occasionally (5-8% of cases) 12 , it is antibodies in the recipient's plasma that are involved and rarely an antibody-antigen reaction in pooled products e.g. platelets from different donors. There is also some evidence that a proportion of cases are non-immunologically mediated and triggered by biologically active lipids or cytokines 5, 9 . These have been implicated in a "2 hit" hypothesis 2,5,7 . The first "hit" is the clinical con-dition of the patient. Systemic inflammatory response syndrome or sepsis primes the neutrophils and polymorphonuclear cells (PMNs), and activates the pulmonary endothelial cells causing sequestration of the PMNs. The second "hit" involves transfusion of either anti-leucocyte antibodies or lipids and cytokines from stored blood. These biological response modifiers activate the sequestered PMNs, causing endothelial damage and capillary leak. This hypothesis may explain the incidence of TRALI in some patients but not others transfused with blood products from the same donor. It would also explain cases of suspected TRALI in which there is no evidence of anti-leucocyte antibodies in donor or recipient 7 . The case described, having a pancreatic inflammatory mass, may fit this category, with anti-HLA class II antibodies detected in one FFP acting as the biologic response modifier for the second "hit".
Whatever the mechanism, thorough haematological investigation is required so that implicated donors, usually multiparous females sensitized from fetal white cells, can be removed from the donor pool. If recipient anti-leucocyte antibodies are detected, then leucocyte-depleted products or leucocyte depletion would be indicated for subsequent transfusions. The U.K. National Blood Service (NBS), accepts only male plasma donations for FFP, as part of their "TRALI Risk Reduction Project" 13 .
There is no specific test for TRALI and positive tests, at best, can only support the clinical evidence in a suspected case. The basis of haematological investigations is the detection of anti-leucocyte antibodies in the suspect donor or recipient's serum. Implicated antibodies are HLA class I or II or neutrophil specific antibodies. If antibodies are detected, antibody-antigen compatibility testing is carried out between recipient neutrophils and all suspect donor serum, or donor neutrophils and recipient serum. The ability to test all suspected donor serum is limited by the fact that the remaining plasma in implicated donor bags is often insufficient in volume. The donors are often not recalled, so testing for antibodies is only performed when the donor returns to donate. Therefore, some cases can never be confirmed. For this reason, only 4 out of the 9 Australian cases reported during a 27 month period in Australia between 1999 and 2001 could be confirmed by antigen-antibody testing 4 . The remaining cases were clinical diagnoses.
ACUTE MANAGEMENT
A TRALI Consensus Conference was held in Canada in March 2004. The Consensus Panel's statement will report on the epidemiology, patho-genesis, diagnosis and treatment of the condition, but their findings are not due to be published until 2005. The following is a suggested plan of management based on the current literature and our own clinical experience.
TRALI should be considered in any patient presenting with dyspnoea, hypoxia and bilateral pulmonary infiltrates up to 24 hours after transfusion of any blood product 13 . At presentation, TRALI is often indistinguishable from other causes of ARDS. At present, there remains no specific treatment for TRALI and management commences with supportive therapies, i.e. oxygen, continuous positive airway pressure or intermittent positive airway pressure, intravenous fluids and inotropes. This means that the majority of patients require critical care. Precipitating factors must then be investigated: echocardiography, measurement of cardiac output, filling pressures, myocardial infarction and sepsis screen, and plasma tryptase. These investigations will help exclude cardiogenic shock, fluid overload, and other noncardiogenic aetiologies such as anaphylaxis or bacterial septicaemia. The following laboratory tests are also required: full blood count (FBC) and differential, serum albumin (and albumin content of tracheal aspirate) and FBC specimen for DNA preparation. All blood product bags must be salvaged and returned to the blood bank for antibody testing and septic screen. High dose steroid therapy has been used in previous documented cases, on the assumption that the pathogenesis of the condition is immunological. However, there is no direct evidence of benefit 1 .
To maximize chances of a positive outcome, a team approach is essential. This team needs to include anaesthetists, intensivists, haematologists and the blood transfusion department. This combination of disciplines will aid prompt and appropriate investigations, enabling management of implicated donors and recipients, thus reducing further incidents of TRALI.
In conclusion, we have described a case of apparent TRALI, an increasing yet apparently under-diagnosed and under-appreciated problem in transfusion practice. This case illustrates that the diagnosis of TRALI is principally a clinical one. Those involved in transfusions of plasma containing blood products need to remember TRALI in their differential diagnosis, if pulmonary oedema presents during or up to 24 hours after a transfusion.
